---
schema_version: "secwatch.filing_event.v1"
accession: "0001854270-24-000050"
form_type: "8-K"
ticker: "SNTI"
cik: "0001854270"
company_name: "Senti Biosciences, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T07:04:37.367206+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Senti Bio Q1 net loss $12.1M; SENTI-202 patient dosing on track for Q2 2024

## Summary
- Cash and equivalents $23.7M at March 31, 2024; additional $18.9M receivable from GeneFab.
- Net loss $12.1M ($0.26 per share); R&D expenses rose to $8.8M from $7.1M on manufacturing costs.
- SENTI-202 Phase 1 trial for AML on track to dose first patient in Q2 2024; initial efficacy data by year-end 2024.
- Pilot trial of SENTI-301A for HCC in China (Celest partnership) expects first patient dosing in Q2 2024.
- Presented three abstracts at ASGCT 2024, including novel CAR discovery and engineered synthetic switches.

## SEC filing metadata
- accession: 0001854270-24-000050
- form_type: 8-K
- ticker: SNTI
- cik: 0001854270
- company_name: Senti Biosciences, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1854270/000185427024000050/0001854270-24-000050-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1854270/000185427024000050/snti-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001854270-24-000050
- JSON: https://secwatch.observer/filing/0001854270-24-000050.json
- Plain text: https://secwatch.observer/filing/0001854270-24-000050.txt

## Key facts
- Earnings Releases
  Senti Biosciences, Inc. reported first quarter of 2024 results: net income Net loss was $12.1 million, or $0.26 per basic and diluted share, EPS $0.26 per basic and diluted share.
  - Period: first quarter of 2024
  - Net income: Net loss was $12.1 million, or $0.26 per basic and diluted share
  - EPS: $0.26 per basic and diluted share
  - Result: reported results
  source text: Senti Biosciences, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1854270/000185427024000050/0001854270-24-000050-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.